QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Signal Management During Pharmacovigilance Inspections

Test your understanding of the concepts covered by Signal Management During Pharmacovigilance Inspections.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which vendor-control evidence would best address whether an outsourced detection tool remains fit for purpose?

A marketing brochure describing the vendor's software Acceptance testing, documented validation, change control and periodic re-validation records An informal statement from a vendor employee A list of unrelated vendor customers

Question 2 of 10 A potential signal is closed after an initial review, but the file contains no rationale or evidence of the review. Why is this particularly problematic?

Potential signals may never be closed under pharmacovigilance procedures An unexplained closure prevents inspectors from evaluating whether the decision was justified and consistently applied Closure automatically requires submission of a revised RMP The absence of a statistical output proves that the signal was clinically important

Question 3 of 10 Why should signal assessments consider multiple evidence sources such as ICSRs, clinical trial data, literature and registries?

Because each source has identical strengths and limitations To support an integrated evaluation of the association, its plausibility, alternatives and potential impact Because spontaneous reports cannot be used in signal management To ensure that every source produces a statistically significant result

Question 4 of 10 In the worked example, why did the combination of disproportionality, temporal clustering and positive dechallenge strengthen the assessment?

Each finding independently proves causality beyond doubt Converging statistical, temporal and clinical evidence supported a possible-to-probable association while still requiring consideration of alternatives The findings eliminated the need for individual case review Positive dechallenge makes exposure estimates and clinical trial data irrelevant

Question 5 of 10 An inspector asks how a potential observation progressed to a decision and subsequent risk-minimisation activity. Which evidence would provide the most complete answer?

Only the final risk-minimisation educational material The signal master file linking detection and validation records, assessment rationale, committee decisions, regulatory communication and implementation evidence Only the product's current SmPC Only the QPPV's job description

Question 6 of 10 In the worked example, why was the absence of acute liver injury cases in clinical trials not sufficient to dismiss the spontaneous-reporting signal?

Clinical trial data are never relevant to signal assessment The trial exposure was limited and differences between trial populations and post-authorisation use can affect the ability to observe rare events Spontaneous reports always provide stronger evidence than clinical trials A disproportionality result cannot be evaluated using clinical trial data

Question 7 of 10 Which responsibility best describes the QPPV's role in signal management according to the article?

Personally perform every disproportionality analysis Retain visibility of important safety information and have authority to escalate when appropriate Approve every individual case narrative before database entry Delegate all signal decisions to vendors because the QPPV is not a scientific assessor

Question 8 of 10 Which practice best supports consistent implementation of signal management across products and teams?

Allow each assessor to use undocumented personal approaches Use current, version-controlled SOPs and mandatory templates with defined minimum content and roles Retain only final conclusions and discard working records Rely on committee members' institutional memory

Question 9 of 10 Which approach is most consistent with the article's expectations for selecting a signal-detection methodology?

Use the most complex available algorithm regardless of product characteristics Use only manual review because automated methods are not sufficient for inspections Select and justify a scientifically appropriate and proportionate method for the product and available data Change methods frequently so that different potential signals can be identified

Question 10 of 10 Which action most directly demonstrates that follow-up from a signal decision was implemented rather than merely planned?

A draft committee agenda mentioning a possible RMP update An action tracker with owners and due dates together with the final RMP change, submission evidence and monitoring records A verbal statement that the signal remains under review A historical detection threshold document

Knowledge Assessment: Signal Management During Pharmacovigilance Inspections

Cookie Settings